Joga Ramesh, Gadekar Kailas Vijay, Gandhi Kajal, Sowndharya M, Waikar Sonali, Raghuvanshi Rajeev Singh, Srivastava Saurabh
Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, 500037, India.
Central Drug Standard Control Organization (CDSCO), Ministry of Health & Family Welfare, Government of India, Directorate General of Health Services, New Delhi, India.
Ther Innov Regul Sci. 2025 Jul;59(4):790-807. doi: 10.1007/s43441-025-00775-1. Epub 2025 May 5.
The 505(b)(2) pathway, established by the USFDA, enables faster approval of new drug applications (NDAs) by allowing partial reliance on existing clinical data. This regulatory mechanism fosters innovation by encouraging new formulations, combinations, and delivery systems, accelerating the availability of advanced therapeutics.
This study provides a comprehensive analysis of 505(b)(2) NDA approvals from 2019 to 2023, with an emphasis on trends, major players, therapeutic targets, and dosage form diversity. Furthermore, the impact of regulatory exclusivity strategies on market dynamics and drug pricing is explored.
Approval data was gathered from the USFDA database and further classified by reformulation type, therapeutic area, primary players, and dosage form. The study also analyzed the therapeutic equivalence codes and the influence of non-patent exclusivity strategies on market competition to identify trends and the prevalence of product types across therapeutic categories.
Our findings reveal a strong presence of reformulations, with new dosage forms (Type 3) and new formulations or other differences (Type 5) accounting for a substantial portion of approvals. Cancer (16.7%), CNS disorders (16.2%), and anti-infective treatments emerged as key therapeutic areas. Teva Pharmaceuticals USA Inc. was the leading entity by approval count. Parenteral dosage forms dominated at 40.3%, followed by tablets at 20.6%. Exclusivity strategies, notably three year's new clinical investigation exclusivity, impacted drug pricing and competitive positioning.
The 505(b)(2) pathway proves instrumental in advancing pharmaceutical innovation and expediting access to therapies targeting unmet needs. These insights offer value for regulatory professionals, drug developers, and policymakers in optimizing development and market strategies to enhance drug accessibility. Companies must remain vigilant and proactive in anticipating potential blocking exclusivities to secure successful approvals.
美国食品药品监督管理局（USFDA）设立的505(b)(2)途径允许部分依赖现有临床数据，从而能够更快地批准新药申请（NDA）。这种监管机制通过鼓励新剂型、新组合和新给药系统来促进创新，加速先进治疗药物的上市。
本研究对2019年至2023年的505(b)(2) NDA批准情况进行了全面分析，重点关注趋势、主要参与者、治疗靶点和剂型多样性。此外，还探讨了监管独占策略对市场动态和药品定价的影响。
批准数据从USFDA数据库收集，并进一步按重新配方类型、治疗领域、主要参与者和剂型进行分类。该研究还分析了治疗等效性代码以及非专利独占策略对市场竞争的影响，以确定各治疗类别的趋势和产品类型的流行情况。
我们的研究结果显示重新配方的情况很普遍，新剂型（3类）和新配方或其他差异（5类）占批准的很大一部分。癌症（16.7%）、中枢神经系统疾病（16.2%）和抗感染治疗成为关键治疗领域。美国梯瓦制药公司是获批数量最多的领先企业。注射剂型占主导地位，为40.3%，其次是片剂，为20.6%。独占策略，特别是三年的新临床研究独占权，影响了药品定价和竞争定位。
505(b)(2)途径被证明有助于推动制药创新，并加快获得针对未满足需求的治疗方法。这些见解为监管专业人员、药物开发者和政策制定者优化开发和市场策略以提高药物可及性提供了价值。公司必须保持警惕并积极主动地预测潜在的阻碍独占权，以确保成功获批。
